Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus TARPEYO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus TARPEYO.
CORTIFOAM vs TARPEYO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
TARPEYO (budesonide) is a corticosteroid with anti-inflammatory activity. It acts by binding to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines and immune cell activation, thereby reducing proteinuria in IgA nephropathy.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
16 mg/kg intravenously once daily on Days 1-5 of each 28-day cycle.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is approximately 27.3 hours (range 21-36 hours) in patients with IgA nephropathy. This supports once-weekly subcutaneous dosing without dose adjustment over the dosing interval.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily hepatic metabolism, with <1% excreted unchanged in urine and <1% in feces. Elimination is predominantly via biliary excretion of metabolites into feces, accounting for >90% of total clearance.
Category C
Category C
Corticosteroid
Corticosteroid